BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-73712

Evasion of apoptosis is a hallmark of cancer, and reversing this process by inhibition of survival signaling pathways is a potential therapeutic strategy. Phosphoinositide 3-kinase (PI3K) signaling can promote cell survival and is upregulated in solid tumor types, including colorectal cancer (CRC),...

Full description

Saved in:
Bibliographic Details
Published in:Neoplasia (New York, N.Y.) N.Y.), 2014-02, Vol.16 (2), p.147-157
Main Authors: Potter, Danielle S, Kelly, Paul, Denneny, Olive, Juvin, Veronique, Stephens, Len R, Dive, Caroline, Morrow, Christopher J
Format: Article
Language:eng
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3978395
title BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-73712
format Article
creator Potter, Danielle S
Kelly, Paul
Denneny, Olive
Juvin, Veronique
Stephens, Len R
Dive, Caroline
Morrow, Christopher J
ispartof Neoplasia (New York, N.Y.), 2014-02, Vol.16 (2), p.147-157
description Evasion of apoptosis is a hallmark of cancer, and reversing this process by inhibition of survival signaling pathways is a potential therapeutic strategy. Phosphoinositide 3-kinase (PI3K) signaling can promote cell survival and is upregulated in solid tumor types, including colorectal cancer (CRC), although these effects are context dependent. The role of PI3K in tumorigenesis combined with their amenability to specific inhibition makes them attractive drug targets. However, we observed that inhibition of PI3K in HCT116, DLD-1, and SW620 CRC cells did not induce apoptotic cell death. Moreover, these cells were relatively resistant to the Bcl-2 homology domain 3 (BH3) mimetic ABT-737, which directly targets the Bcl-2 family of apoptosis regulators. To test the hypothesis that PI3K inhibition lowers the apoptotic threshold without causing apoptosis per se , PI3K inhibitors were combined with ABT-737. PI3K inhibition enhanced ABT-737-induced apoptosis by 2.3- to 4.5-fold and reduced expression levels of MCL-1, the resistance biomarker for ABT-737. PI3K inhibition enhanced ABT-737-induced apoptosis a further 1.4- to 2.4-fold in CRC cells with small interfering RNA-depleted MCL-1, indicative of additional sensitizing mechanisms. The observation that ABT-737-induced apoptosis was unaffected by inhibition of PI3K downstream effectors AKT and mTOR, implicated a novel PI3K-dependant pathway. To elucidate this, an RNA interference (RNAi) screen of potential downstream effectors of PI3K signaling was conducted, which demonstrated that knockdown of the TEC kinase BMX sensitized to ABT-737. This suggests that BMX is an antiapoptotic downstream effector of PI3K, independent of AKT.
language eng
source ScienceDirect; BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS; Open Access: PubMed Central
identifier ISSN: 1522-8002
fulltext fulltext
issn 1522-8002
1476-5586
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-05-24T21%3A17%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BMX%20Acts%20Downstream%20of%20PI3K%20to%20Promote%20Colorectal%20Cancer%20Cell%20Survival%20and%20Pathway%20Inhibition%20Sensitizes%20to%20the%20BH3%20Mimetic%20ABT-73712&rft.jtitle=Neoplasia%20(New%20York,%20N.Y.)&rft.au=Potter,%20Danielle%20S&rft.date=2014-02-01&rft.volume=16&rft.issue=2&rft.spage=147&rft.epage=157&rft.pages=147-157&rft.issn=1522-8002&rft.eissn=1476-5586&rft_id=info:doi/&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_3978395%3C/pubmedcentral%3E%3Cgrp_id%3Ecdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_39783953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24709422
container_title Neoplasia (New York, N.Y.)
container_volume 16
container_issue 2
container_start_page 147
container_end_page 157
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3978395</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_3978395</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_39783953</originalsourceid><addsrcrecordid>eNqljEFLwzAYhoMoblP_w_cHCm3SNu1FWKuyIYPCdtgtZN03G0mTkWQd8-7_XgUvnj29D-8Dzw2ZJinPoywr8tuRM0qjIo7phMy8_4zjJE84vycTmvK4TCmdku9qtYV5Gzy82LPxwaHswR6gWbJ3CBYaZ3sbEGqrrcM2SA21NC06qFFrWJ_coIbxlGYPjQzdWV5gaTq1U0FZA2s0fqQv9D-x0CFUCwYr1WNQLcyrTcQZT-gjuTtI7fHpdx_I89vrpl5Ex9Oux32LJjipxdGpXrqLsFKJv8aoTnzYQbCSF6zM2L8DV999aYI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><isCDI>true</isCDI><recordtype>article</recordtype></control><display><type>article</type><title>BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-73712</title><source>ScienceDirect</source><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><source>Open Access: PubMed Central</source><creator>Potter, Danielle S ; Kelly, Paul ; Denneny, Olive ; Juvin, Veronique ; Stephens, Len R ; Dive, Caroline ; Morrow, Christopher J</creator><creatorcontrib>Potter, Danielle S ; Kelly, Paul ; Denneny, Olive ; Juvin, Veronique ; Stephens, Len R ; Dive, Caroline ; Morrow, Christopher J</creatorcontrib><description>Evasion of apoptosis is a hallmark of cancer, and reversing this process by inhibition of survival signaling pathways is a potential therapeutic strategy. Phosphoinositide 3-kinase (PI3K) signaling can promote cell survival and is upregulated in solid tumor types, including colorectal cancer (CRC), although these effects are context dependent. The role of PI3K in tumorigenesis combined with their amenability to specific inhibition makes them attractive drug targets. However, we observed that inhibition of PI3K in HCT116, DLD-1, and SW620 CRC cells did not induce apoptotic cell death. Moreover, these cells were relatively resistant to the Bcl-2 homology domain 3 (BH3) mimetic ABT-737, which directly targets the Bcl-2 family of apoptosis regulators. To test the hypothesis that PI3K inhibition lowers the apoptotic threshold without causing apoptosis per se , PI3K inhibitors were combined with ABT-737. PI3K inhibition enhanced ABT-737-induced apoptosis by 2.3- to 4.5-fold and reduced expression levels of MCL-1, the resistance biomarker for ABT-737. PI3K inhibition enhanced ABT-737-induced apoptosis a further 1.4- to 2.4-fold in CRC cells with small interfering RNA-depleted MCL-1, indicative of additional sensitizing mechanisms. The observation that ABT-737-induced apoptosis was unaffected by inhibition of PI3K downstream effectors AKT and mTOR, implicated a novel PI3K-dependant pathway. To elucidate this, an RNA interference (RNAi) screen of potential downstream effectors of PI3K signaling was conducted, which demonstrated that knockdown of the TEC kinase BMX sensitized to ABT-737. This suggests that BMX is an antiapoptotic downstream effector of PI3K, independent of AKT.</description><identifier>ISSN: 1522-8002</identifier><identifier>EISSN: 1476-5586</identifier><identifier>PMID: 24709422</identifier><language>eng</language><publisher>Neoplasia Press Inc</publisher><ispartof>Neoplasia (New York, N.Y.), 2014-02, Vol.16 (2), p.147-157</ispartof><rights>Copyright © 2014 Neoplasia Press, Inc. All rights reserved 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978395/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978395/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,734,787,791,892,54176,54178</link.rule.ids></links><search><creatorcontrib>Potter, Danielle S</creatorcontrib><creatorcontrib>Kelly, Paul</creatorcontrib><creatorcontrib>Denneny, Olive</creatorcontrib><creatorcontrib>Juvin, Veronique</creatorcontrib><creatorcontrib>Stephens, Len R</creatorcontrib><creatorcontrib>Dive, Caroline</creatorcontrib><creatorcontrib>Morrow, Christopher J</creatorcontrib><title>BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-73712</title><title>Neoplasia (New York, N.Y.)</title><description>Evasion of apoptosis is a hallmark of cancer, and reversing this process by inhibition of survival signaling pathways is a potential therapeutic strategy. Phosphoinositide 3-kinase (PI3K) signaling can promote cell survival and is upregulated in solid tumor types, including colorectal cancer (CRC), although these effects are context dependent. The role of PI3K in tumorigenesis combined with their amenability to specific inhibition makes them attractive drug targets. However, we observed that inhibition of PI3K in HCT116, DLD-1, and SW620 CRC cells did not induce apoptotic cell death. Moreover, these cells were relatively resistant to the Bcl-2 homology domain 3 (BH3) mimetic ABT-737, which directly targets the Bcl-2 family of apoptosis regulators. To test the hypothesis that PI3K inhibition lowers the apoptotic threshold without causing apoptosis per se , PI3K inhibitors were combined with ABT-737. PI3K inhibition enhanced ABT-737-induced apoptosis by 2.3- to 4.5-fold and reduced expression levels of MCL-1, the resistance biomarker for ABT-737. PI3K inhibition enhanced ABT-737-induced apoptosis a further 1.4- to 2.4-fold in CRC cells with small interfering RNA-depleted MCL-1, indicative of additional sensitizing mechanisms. The observation that ABT-737-induced apoptosis was unaffected by inhibition of PI3K downstream effectors AKT and mTOR, implicated a novel PI3K-dependant pathway. To elucidate this, an RNA interference (RNAi) screen of potential downstream effectors of PI3K signaling was conducted, which demonstrated that knockdown of the TEC kinase BMX sensitized to ABT-737. This suggests that BMX is an antiapoptotic downstream effector of PI3K, independent of AKT.</description><issn>1522-8002</issn><issn>1476-5586</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqljEFLwzAYhoMoblP_w_cHCm3SNu1FWKuyIYPCdtgtZN03G0mTkWQd8-7_XgUvnj29D-8Dzw2ZJinPoywr8tuRM0qjIo7phMy8_4zjJE84vycTmvK4TCmdku9qtYV5Gzy82LPxwaHswR6gWbJ3CBYaZ3sbEGqrrcM2SA21NC06qFFrWJ_coIbxlGYPjQzdWV5gaTq1U0FZA2s0fqQv9D-x0CFUCwYr1WNQLcyrTcQZT-gjuTtI7fHpdx_I89vrpl5Ex9Oux32LJjipxdGpXrqLsFKJv8aoTnzYQbCSF6zM2L8DV999aYI</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Potter, Danielle S</creator><creator>Kelly, Paul</creator><creator>Denneny, Olive</creator><creator>Juvin, Veronique</creator><creator>Stephens, Len R</creator><creator>Dive, Caroline</creator><creator>Morrow, Christopher J</creator><general>Neoplasia Press Inc</general><scope>5PM</scope></search><sort><creationdate>20140201</creationdate><title>BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-73712</title><author>Potter, Danielle S ; Kelly, Paul ; Denneny, Olive ; Juvin, Veronique ; Stephens, Len R ; Dive, Caroline ; Morrow, Christopher J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_39783953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Potter, Danielle S</creatorcontrib><creatorcontrib>Kelly, Paul</creatorcontrib><creatorcontrib>Denneny, Olive</creatorcontrib><creatorcontrib>Juvin, Veronique</creatorcontrib><creatorcontrib>Stephens, Len R</creatorcontrib><creatorcontrib>Dive, Caroline</creatorcontrib><creatorcontrib>Morrow, Christopher J</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neoplasia (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Potter, Danielle S</au><au>Kelly, Paul</au><au>Denneny, Olive</au><au>Juvin, Veronique</au><au>Stephens, Len R</au><au>Dive, Caroline</au><au>Morrow, Christopher J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-73712</atitle><jtitle>Neoplasia (New York, N.Y.)</jtitle><date>2014-02-01</date><risdate>2014</risdate><volume>16</volume><issue>2</issue><spage>147</spage><epage>157</epage><pages>147-157</pages><issn>1522-8002</issn><eissn>1476-5586</eissn><notes>These authors contributed equally to this work.</notes><abstract>Evasion of apoptosis is a hallmark of cancer, and reversing this process by inhibition of survival signaling pathways is a potential therapeutic strategy. Phosphoinositide 3-kinase (PI3K) signaling can promote cell survival and is upregulated in solid tumor types, including colorectal cancer (CRC), although these effects are context dependent. The role of PI3K in tumorigenesis combined with their amenability to specific inhibition makes them attractive drug targets. However, we observed that inhibition of PI3K in HCT116, DLD-1, and SW620 CRC cells did not induce apoptotic cell death. Moreover, these cells were relatively resistant to the Bcl-2 homology domain 3 (BH3) mimetic ABT-737, which directly targets the Bcl-2 family of apoptosis regulators. To test the hypothesis that PI3K inhibition lowers the apoptotic threshold without causing apoptosis per se , PI3K inhibitors were combined with ABT-737. PI3K inhibition enhanced ABT-737-induced apoptosis by 2.3- to 4.5-fold and reduced expression levels of MCL-1, the resistance biomarker for ABT-737. PI3K inhibition enhanced ABT-737-induced apoptosis a further 1.4- to 2.4-fold in CRC cells with small interfering RNA-depleted MCL-1, indicative of additional sensitizing mechanisms. The observation that ABT-737-induced apoptosis was unaffected by inhibition of PI3K downstream effectors AKT and mTOR, implicated a novel PI3K-dependant pathway. To elucidate this, an RNA interference (RNAi) screen of potential downstream effectors of PI3K signaling was conducted, which demonstrated that knockdown of the TEC kinase BMX sensitized to ABT-737. This suggests that BMX is an antiapoptotic downstream effector of PI3K, independent of AKT.</abstract><pub>Neoplasia Press Inc</pub><pmid>24709422</pmid></addata></record>